News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
QIAstat-Dx BCID GPF Plus AMR Panel detects 20 pathogen targets and 10 antimicrobial resistance markers from positive blood cultures in about one hour FDA clearance marks QIAGEN's entry into U.S. bloodstream infection testing and establishes the first member of a planned QIAstat-Dx BCID panel …
Sharemaestro market context Price above Trend Line 52 weeks -14.1%Metagenomi Therapeutics (MGX) faces significant financial challenges, with forecasted declines in revenue and earnings. Analyst consensus shows a downward trend in revenue estimates and price targets, alongside consistent net losses. The company has also experienced volatility in its stock price and is currently facing …
Have you assessed how the international operations of Qiagen (QGEN) performed in the quarter ended June 2026? For this diagnostic products maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. …
Sharemaestro market context Price above Trend Line 52 weeks -14.1%HC Wainwright has reiterated its "buy" rating for Ultragenyx Pharmaceutical (RARE) with a $50 price target, suggesting a 93% upside from its current stock price. This aligns with a "Moderate Buy" consensus among analysts, who project an average target of $57.82. The biopharmaceutical company …
Volkswagen (VW) is preparing a significant shake-up of its US operations, bringing in new leadership and broadening its model line-up to include a pickup truck, German business newspaper Handelsblatt reported. The German carmaker is reviewing its entire US model range, with the source indicating …
Sharemaestro market context Price below Trend Line 52 weeks -28.9%Ultragenyx Pharmaceutical (RARE) reported a Q2 2026 revenue gain of US$214 million, up from US$167 million year-over-year, and a narrower net loss of US$92 million compared to US$115 million. While these results support the investment case for its rare disease and gene therapy portfolio, …
On August 4, 2026, Ultragenyx Pharmaceutical Inc. reported second-quarter revenue of US$214 million versus US$167 million a year earlier, while quarterly net loss narrowed to US$92 million from US$115 million and basic loss per share from continuing operations improved to US$0.90 from US$1.17. Despite …
Exagen Inc. (NASDAQ:XGN) recently surpassed its latest quarterly revenue and loss estimates, leading analysts to become more optimistic about its future. They have modestly increased their revenue and loss per share predictions for 2026 and raised the price target by 15% to US$9.86. Despite …
The Manufacturers Life Insurance Company recently acquired 63,219 shares of Qiagen N.V. (NYSE:QGEN) worth approximately $2.52 million. This purchase is part of broader institutional investment, with various firms like Boston Partners, Norges Bank, and Price T Rowe Associates also holding significant stakes, bringing total …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Ultragenyx Pharmaceutical stock is coming off a difficult longer term stretch, with the share price down about 72.1% over five years. Current valuation checks …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Ultragenyx Pharmaceutical (RARE) released its second quarter 2026 results on 4 August, reporting revenue of US$214 million and a net loss of US$92 million. …
In early August 2026, Niagen Bioscience Inc. reported slightly lower quarterly sales and net income year on year, while also expanding access to its Tru Niagen® healthy‑aging NAD+ supplement via Walmart.com, initially offering 300 mg bottles in 30‑ and 90‑count formats. A new peer‑reviewed …
This page provides news and analysis for Agenus Inc (AGEN) stock, a company in the Biotechnology & Medical Research sector. It lists the current stock price, market cap, and P/E ratio, alongside links to financial data, ownership, dividends, and discussions. The news section highlights …
AGENUS INC reported a strong second quarter for 2026, with revenue reaching $34.5 million, a 34.3% increase year-over-year. The company achieved a net income of $38.6 million for the year-to-date, contrasting sharply with a loss in the prior year, and diluted EPS of $0.96. …
QIAGEN N.V. (NYSE: QGEN) reported Q2 2026 net sales of $535.04 million and net income of $103.401 million, with diluted EPS of $0.50. The company executed a $496.7 million synthetic share repurchase in January 2026, reducing outstanding shares by 5.0%, and approved a $0.35 …
Qiagen N.V.'s average price target has been increased from $43.87 to $44.52 by 17 analysts, suggesting a 7% potential upside based on its closing price. The consensus rating remains a "Buy" from 22 covering analysts. Investors can explore more price target data and analyst …
Adagene (NASDAQ:ADAG) CEO Peter Luo recently increased his holdings in the company by purchasing 22,966 shares at an average price of $3.65, totaling approximately $83,826. This transaction, along with an additional purchase of 279 shares the following day, boosted his ownership by 51.04%. Despite …
Adagene CEO Peter Luo has purchased 23,245 American Depositary Shares (ADS) at approximately $3.65 per share, totaling $84,763.97. Following this transaction, his directly held ADS position increased to 68,245 shares, in addition to 112,500 restricted stock units. This information was generated using AI based …
This page provides an interactive stock chart and related news for Adagene Inc. (ADRs) under the ticker US0053291078.SG on Yahoo Finance. The stock is currently trading at 3.7800 EUR
Agenus Inc. has filed to resell up to 78 million shares. This announcement follows recent positive news for the company, including strong second-quarter earnings, a price target adjustment from B. Riley, and significant funding from RA Capital Management, L.P. The biotech company is focused …
Agenus Inc. (AGEN) reported a second-quarter loss of $550,000, translating to 1 cent per share. The biotechnology company achieved $34.5 million in revenue for the period. Agenus shares have more than doubled since the start of the year, with a 46% increase in the …
This article is a 6-K filing by Qiagen NV, which is a report for a foreign private issuer. These reports are typically related to financial reporting and other significant company updates that are required by regulatory bodies.
State Street Corporation has disclosed a 6.3% ownership stake in Ultragenyx Pharmaceutical Inc., according to a Schedule 13G filing. The investment firm reported beneficial ownership of 6,158,766 shares, primarily through its investment management subsidiaries. While State Street holds no sole voting or dispositive power, …
Quantinno Capital Management LP significantly reduced its stake in Qiagen N.V. by 40.6% in the first quarter, now holding 132,392 shares valued at approximately $5.3 million. Despite this, Qiagen's recent quarterly earnings exceeded expectations, with EPS of $0.62 and revenue of $535 million, and …
QIAGEN N.V. has filed its Form 6-K Report of Foreign Private Issuer for the quarterly period ended June 30, 2026, with the United States Securities and Exchange Commission (SEC). The document is now accessible on QIAGEN's website. This release provides important capital market information …
QIAGEN N.V. exceeded its Q2 2026 EPS outlook with adjusted diluted EPS of $0.62, against an outlook of at least $0.60 CER, and reaffirmed its full-year 2026 guidance for net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 …
AGENUS INC (AGEN) has granted 100,000 stock options to its Chief Medical Officer, Steven J. O'Day, on August 5, 2026. These options have an exercise price of $7.7800 per share and will expire on August 5, 2036. The options vest over three years, with …
Agenus Inc. has awarded 50,000 stock options to director Timothy Wright under its 2019 Amended and Restated Equity Incentive Plan. The options have an exercise price of $7.78 per share, expire on August 5, 2036, and will vest over three years. This grant aims …
This article provides a quick look at today's analyst ratings for Qiagen NV (QGEN.US), forecasting a target price between $45.50 and $46.09. It highlights the general sentiment and price targets from various financial institutions.
Metagenomi Therapeutics Inc is projected to report a loss of 57 cents per share. This earnings preview from Refinitiv indicates the company's expected financial performance. The full article is available on TradingView, offering unlimited access to news from various sources.
QIAGEN N.V. (NYSE: QGEN) announced it will convene its 2026 Annual General Meeting on June 24, 2026. Shareholders will vote on a proposed cash dividend of $0.35 per ordinary share, totaling approximately $72 million, payable July 14, 2026. Additionally, the agenda includes authorizing a …
Sharemaestro market context Price above Trend Line 52 weeks -14.1%Search by ticker symbol or company name and select a result to open its chart.